All Episodes
JCO Precision Oncology Conversations — 69 episodes
Phase II Study of Seribantumab in Tumors Harboring NRG1 Fusions
JCO PO Article Insights: Circulating Cancer Genome Atlas Study 5-year Outcomes
JCO PO Article Insights: Analytical Validation of Tumor-Informed ctDNA Assays for MRD
Oncotype DX Breast Recurrence Score® Results from Paired CNB & SE Specimens
ctDNA in Metastatic Invasive Lobular Carcinoma
JCO PO Article Insights: Circulating Tumor DNA in Germ Cell Tumors
FGFR2b Prevalence in Advanced GC: FORTITUDE-101 Prescreening
Palbociclib in Tumors with CDKN2A Loss or Mutation
FGFR3 Alteration Status and Immunotherapy in Urothelial Cancer
JCO PO Article Insights: Genomic Risk Classifiers in Localized Prostate Cancer
DLL3 and SEZ6 Expression in Neuroendocrine Carcinomas
Somatic Mutations of Colorectal Cancer by Birth Cohort
Areas of Uncertainty in Pancreatic Cancer Surveillance
Lynch Syndrome Mortality in the Immunotherapy Era
JCO PO Article Insights: A Retrospective Analysis to Identify ICI-Sensitive Populations
Genomic Profile of Small Cell Bladder, Lung and Urothelial Cancer
JCO PO Article Insights: MUC16 Directed BiTE Therapy in Epithelioid Sarcoma
BRCA-Altered Uterine Sarcoma Treated with PARP Inhibitors
JCO PO Article Insights: Prognostic Gene Expression Signature and MYC Expression in Osteosarcoma
JCO PO Article Insights: Prognostic Gene Expression Signature and MYC Expression in Osteosarcoma
JCO PO Article Insights: Real-Time Monitoring in RCC with ctDNA
A Position Paper on ctDNA Testing in Clinical Trials
JCO PO Article Insights: TMB and Real-World ICI Outcomes in Melanoma
Effectiveness and Cost-Effectiveness of Gene Panels in Melanoma
JCO PO Article Insights: Exceptional Responders with Abexinostat and Pazopanib
Prognostic Artificial Intelligence Scores and Outcomes in Nonmetastatic Prostate Cancer
JCO PO Article Insights: Prognostic Artificial Intelligence Nonmetastatic Prostate Cancer
JCO PO Article Insights: Therapy of Infantile Midline Low-Grade Gliomas
Adagrasib Following Sotorasib-Related Hepatotoxicity
JCO PO Article Insights: ctDNA as a Prognostic Biomarker in EGC
Proteomics Predictor for Immunotherapy Benefit
Transcriptome and ctDNA Associates with Pembrolizumab Benefit
JCO PO Article Insights: Germline Pathogenic Variants in Renal Cell Carcinoma
Uptake of Aspirin Chemoprevention in Lynch Syndrome
JCO PO Article Insights: Talazoparib in Solid Tumors with BRCA1/2 Mutation
Transcriptomic Profiling of Non-Localized Prostate Cancer
JCO PO Article Insights: MCED Test Preferentially Detects High-Grade Prostate Cancers
Molecular Characteristics of Early-Onset Biliary Tract Cancer
JCO PO Article Insights: Publication Trends in JCO Precision Oncology
CCR Score to Predict ADT Benefit in Men with Prostate Cancer
JCO PO Article Insights: Statistical Considerations for Biomarker-Driven Oncology Clinical Trials
JCO PO Article Insights: Role of ctDNA in Appendiceal Cancer
PD-L1 Assay Concordance in Gastric Cancer
JCO PO Article Insights: Serial Post Operative ctDNA Predicts Poor Breast Cancer Outcome
Phase II Study of Erdafitinib in Tumors with FGFR Amplifications and Mutations or Fusions
JCO PO Article Insights: Web-Based Pretest Genetic Education for Prostate Cancer Germline Testing
Liquid Biopsy of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment
JCO PO Article Insights: Microsatellite Instability as a Biomarker in Clinical Practice
Recommendations for the Equitable and Widespread Implementation of Liquid Biopsy
JCO PO Article Insights: Prediction of Adjuvant Pertuzumab Benefit by 80-GS
MultiCancer Detection Test Performance in Symptomatic Individuals
JCO PO Article Insights: Diverse Study Samples in Clinical Trials
Tumor Mutational Burden and Advanced Pancreatic Cancer
Representativeness of Lung-MAP Participants
Perspectives on Universal Germline Testing for Colorectal Cancer
Outcomes of the IMMray PanCan-d Test in High-Risk Individuals
Implementation of the Maine Cancer Genomics Initiative
Pertuzumab + Trastuzumab in Lung Cancer with ERBB2 Alterations
MMR-P Colorectal Cancer in Lynch Syndrome
Real-World NTRK Fusions and TRK Inhibitors in Veterans
Larotrectinib for TRK Fusion - Positive Lung Cancer
ctDNA for Recurrence Prediction in Esophagogastric Cancers
KRAS Variants, G12C, TMB, high PD-L1 Expression in Solid Tumors
Universal Genetic Germline Testing in Solid Tumor Cancer Patients
Tumor Mutational Burden as a Predictor of First-Line Immune Checkpoint Inhibitor Versus Carboplatin Benefit in Cisplatin-Unfit Patients With Urothelial Carcinoma, with Dr. Shilpa Gupta
Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors, with Dr. Mark Stewart
Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures with Dr. Mark Yarchoan
Hyperthermic Intraperitoneal Chemotherapy–Induced Molecular Changes in Humans Validate Preclinical Data in Ovarian Cancer with Dr. Thanh Dellinger
Introducing JCO Precision Oncology and Its Editor in Chief, Dr. James Ford